CG Oncology (CGON) Competitors

Roivant Sciences (NASDAQ:ROIV) and CG Oncology (NASDAQ:CGON) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, media sentiment, profitability, dividends, risk, analyst recommendations and community ranking.

Which has preferable earnings and valuation, ROIV or CGON?

Roivant Sciences has higher revenue and earnings than CG Oncology. Roivant Sciences is trading at a lower price-to-earnings ratio than CG Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$29.05M	263.94	$4.35B	-$0.25	-45.12
CG Oncology	$662K	3,014.46	-$48.61M	-$1.51	-17.34

Which has more risk & volatility, ROIV or CGON?

Roivant Sciences has a beta of 1.16, suggesting that its stock price is 16% more volatile than the S&P 500. Comparatively, CG Oncology has a beta of 0.86, suggesting that its stock price is 14% less volatile than the S&P 500.

Do analysts rate ROIV or CGON?

Roivant Sciences currently has a consensus target price of $17.50, suggesting a potential upside of 55.14%. CG Oncology has a consensus target price of $58.22, suggesting a potential upside of 122.39%. Given CG Oncology's higher probable upside, analysts clearly believe CG Oncology is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.00
CG Oncology	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	3.00

Do insiders and institutionals have more ownership in ROIV or CGON?

64.8% of Roivant Sciences shares are owned by institutional investors. Comparatively, 26.6% of CG Oncology shares are owned by institutional investors. 7.9% of Roivant Sciences shares are owned by company insiders. Comparatively, 7.4% of CG Oncology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Does the MarketBeat Community believe in ROIV or CGON?

Roivant Sciences received 27 more outperform votes than CG Oncology when rated by MarketBeat users. However, 90.63% of users gave CG Oncology an outperform vote while only 78.87% of users gave Roivant Sciences an outperform vote.

Company	Underperform	Outperform
Roivant Sciences	Outperform Votes 56 78.87%	Underperform Votes 15 21.13%
CG Oncology	Outperform Votes 29 90.63%	Underperform Votes 3 9.38%

Is ROIV or CGON more profitable?

Roivant Sciences has a net margin of -119.54% compared to CG Oncology's net margin of -10,642.98%. Roivant Sciences' return on equity of -14.05% beat CG Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-119.54%	-14.05%	-12.81%
CG Oncology	-10,642.98%	-18.97%	-15.36%

Does the media favor ROIV or CGON?

In the previous week, Roivant Sciences had 6 more articles in the media than CG Oncology. MarketBeat recorded 13 mentions for Roivant Sciences and 7 mentions for CG Oncology. CG Oncology's average media sentiment score of 1.34 beat Roivant Sciences' score of 0.71 indicating that CG Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	7 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CG Oncology	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Roivant Sciences beats CG Oncology on 11 of the 17 factors compared between the two stocks.